Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2010
10/28/2010US20100272710 Compositions and methods for treating and preventing aging-associated diseases
10/28/2010US20100272709 Cathepsin l mediated diseases and associated methods and products
10/28/2010US20100272708 Method for the treatment of type and type iv hypersensitivity
10/28/2010US20100272707 Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof
10/28/2010US20100272706 Antivirals
10/28/2010US20100272678 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
10/28/2010US20100272676 Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
10/28/2010US20100272646 Method for inducing lymphoid tissue and modulating intestinal homeostasis
10/28/2010US20100272643 Procaspase 8-Mediated Disease Targeting
10/28/2010US20100272639 Polysaccharide nanoparticles
10/28/2010US20100272636 Anti-CD74 Immunoconjugates and Methods of Use
10/28/2010US20100270202 Method of Immunization Against the 4 Dengue Serotypes
10/28/2010CA2759733A1 Anti-human ror1 antibodies
10/28/2010CA2759727A1 Hydrogels for combinatorial delivery of immune-modulating biomolecules
10/28/2010CA2759583A1 A tuberculosis tb vaccine to prevent reactivation
10/28/2010CA2759506A1 Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
10/28/2010CA2759425A1 Immunogenic epitopes of ngep antigen
10/28/2010CA2759325A1 Replikin-sequences for preventing/treating influenza and determining infectivity/lethality
10/28/2010CA2759146A1 Antibody containing igg2 having amino acid mutation introduced therein
10/28/2010CA2759030A1 Adjuvant cancer therapy
10/28/2010CA2758842A1 Fgfr1c antibody combinations
10/28/2010CA2758733A1 Improved modified live vaccine of mycoplasma bovis, methods of producing modified live mycoplasma bovis vaccines, combination vaccines and methods of treatment
10/28/2010CA2757706A1 A novel cell and therapeutical and diagnostical methods based thereon
10/28/2010CA2757079A1 Control of protein glycosylation and compositions and methods relating thereto
10/28/2010CA2744947A1 Use of epidermal growth factor inhibitors in the treatment of viral infection
10/27/2010EP2243835A2 Antibodies against insulin-like growth factor I receptor and uses thereof
10/27/2010EP2243829A1 Improved humanized anti-human 9-integrin antibody
10/27/2010EP2243791A1 Cloning and recombinant production of Vespula venom protease and methods of use thereof
10/27/2010EP2243789A1 P.gingivalis antigenic composition
10/27/2010EP2243788A1 HIVCON: An HIV immunogen and uses thereof
10/27/2010EP2243493A1 Immunopotentiative composition
10/27/2010EP2243492A1 Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
10/27/2010EP2243491A1 Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
10/27/2010EP2242772A1 Immunoconjugates targeting cd138 and uses thereof
10/27/2010EP2242770A2 Barb4 target which comprises tata-binding protein-associated factor 15, antibody designated barb4, barb4 related antibodies, and methods of making and using same
10/27/2010EP2242768A2 Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
10/27/2010EP2242512A1 Methods for manipulating phagocytosis mediated by cd47
10/27/2010EP2242510A2 Virus-like particles as vaccines for paramyxovirus
10/27/2010EP2242509A1 Biomarker for selecting patients and related methods
10/27/2010EP2021356B1 Hiv vaccine
10/27/2010EP1649011B1 Culture method for keratinocytes and use thereof
10/27/2010EP1567155B1 Administration of dendritic cells partially matured in vitro for the treatment of tumors
10/27/2010EP1537147B1 Antibody anti hla-dr with an increased adcc and inducing cytokine production
10/27/2010EP1487877B1 Compositions and methods for the diagnosis of tumors
10/27/2010EP1119627B1 Ebola virion proteins expressed from venezuelan equine encephalitis (vee) virus replicons
10/27/2010EP1112088B1 Method for detecting connective tissue growth factor for diagnosing a renal disorder
10/27/2010EP0979101B1 Recombinant canine adenovirus 2 (cav2) containing exogenous dna
10/27/2010CN1942583B Optimized expression of HPV 58 L1 in yeast
10/27/2010CN1912141B Identification of genes
10/27/2010CN1617742B Methods for treating cancer by using tumor-derived dentrical cell inhibitory factor antagonist in combination with toll-like receptor agonist
10/27/2010CN1468256B Purification of HBV antigens for use in vaccines
10/27/2010CN1384877B Rescue of mumps virus from cDNA
10/27/2010CN101874042A Method of modifying isoelectric point of antibody via amino acid substitution in cdr
10/27/2010CN101874041A Modified antibody constant region
10/27/2010CN101873862A Composition and therapeutic anti-tumour vaccine
10/27/2010CN101870978A Clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and nucleic acid vaccine thereof
10/27/2010CN101870733A Poultry IL-2 and newcastle disease virus HN gene recombination fusion protein and application thereof
10/27/2010CN101870730A Anti-CD-20 monoclonal antibody
10/27/2010CN101870725A MAGE (Melanoma Antigen Gene)-4 anti-tumor CTL (Cytotoxic T Lymphocyte) epitope peptide and application thereof
10/27/2010CN101870724A PLAC1 (Placenta-specific 1) anti-tumor CTL (Cytotoxic T Lymphocyte) epitope peptide and application thereof
10/27/2010CN101869707A Methods for enhancing innate and adaptive immunity and antigen immunogenicity
10/27/2010CN101869706A Compound astragalus polysaccharides and echinacea purpurea herb nanoemulsion adjuvant and preparation method thereof
10/27/2010CN101869705A Streptococcus iniae vaccine and preparation and application thereof
10/27/2010CN101869704A Single dose immunization against tetanus toxin cation dextran microspheres and preparation method thereof
10/27/2010CN101869703A Application of corynebacterium parvum preparation or non-cell corynebacterium parvum preparation in preparing medicine for preventing and curing bovine mastitis
10/27/2010CN101869702A Vaccine produced by suspended microcarrier cell culture system and method for producing vaccine
10/27/2010CN101869590A Chinese medicinal herba epimedii and propolis flavone immunopotentiator
10/27/2010CN101579527B HLA Specific human cytomegalovirus Multi-epitope adenovirus DNA Vaccine of Chinese population
10/27/2010CN101297967B Novel use of staphylococcus enterotoxin A gene
10/27/2010CN101279092B Applications of VEGF receptor fusion protein in preparation of medicament for curing diseases about angiogenesis
10/27/2010CN101249265B Intravenous injection employ persons hepatitis B immune globulin and method of preparing the same
10/27/2010CN101249261B Kidney syndrome hemorrhagic fever mucosa immune vaccines and method of preparing the same
10/27/2010CN101020894B Avirulent type-2 pig streptococcus strain and its prepn and application
10/26/2010USRE41887 increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system; Type 1 diabetes mellitus
10/26/2010US7820877 Human heavy chain variable regions, human kappa light chain variable regions and encodes only mu isotype; human kappa light chain variable regions and encodes mu and gamma-2 isotypes; double-inactivated mouse Ig locus
10/26/2010US7820807 can bind to and stimulate professional and non-professional human antigen-presenting cells, enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells
10/26/2010US7820789 Streptococcal virulence factor for use in developing vaccines for treatment and prevention of pneumonia, meningitis and bacteraemia
10/26/2010US7820787 Immunotherapy; antitumor agents
10/26/2010US7820786 Synthetic peptides and uses therefore
10/26/2010US7820660 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
10/26/2010US7820633 cytotoxic T-cell mediated killing of disease cells that express a weakly immunogenic or non-immunogenic cell-associated polypeptide antigen in an animal by administering a cytotoxic T-cell epitope and a T-helper lymphocyte
10/26/2010US7820627 with core structure of pentaerythritol used as replacement for sugars; immunomodulators; immunogens within liposomes; tumor antigens; for use as haptens, inhibitors of bacterial-host cell adhesion; septic shock
10/26/2010US7820620 Cripto antagonism of activin and TGF-b signaling
10/26/2010US7820447 drug screening; for carcinomas, especially lymphoma carcinomas
10/26/2010US7820410 Proteins with high immunoreactivity and method for their production
10/26/2010US7820400 Tumor-associated marker
10/26/2010US7820395 diagnostic method and vaccine using a composition comprising truncated r47 protein and truncated r56 protein; reducing HIV viral loads
10/26/2010US7820375 Use of a protein of the CRMP family for treating diseases related to the immune system
10/26/2010US7820185 preventing aggregation of outer membrane vesicles of bacteria; measuring by adjusting zeta potential; use in vaccination
10/26/2010US7820184 Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
10/26/2010US7820183 injected into the lower leg muscle of infants, before applying a first cast for effective therapy in correcting this physical deformity; neuromuscular inhibitors; avoid surgery
10/26/2010US7820182 Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
10/26/2010US7820181 Generating expression vectors comprising myxoviral gene sequences for use as tool in developing vaccines to prevent infection and respiratory sysytem disorders; genetic vaccines and viral diseases
10/26/2010US7820180 Against an antigen-expressing tumor and for inducing an immune response against a sub-dominant epitope of antigen; vaccine has a strain expressing an antigen fused to a truncated LLO protein; cancer vaccines
10/26/2010US7820179 conjugated polymer biodrug for use in treating bone disorders likes osteoporosis or osteopenia, bone fracture
10/26/2010US7820178 VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
10/26/2010US7820172 including a heparin-binding peptide sequence covalently linked to a linker sequence; useful for coating medical devices and as soluble biologics, and as pharmaceutical agents for treating a variety of conditions
10/26/2010US7820171 administering to a ruminant animal with IgY antibodies isolated from eggs from hens immunized with a methanogen antigen; reducing methane gas evolved by the animal to reduce greenhouse gas emission; environmentally friendly
10/26/2010US7820170 monoclonal antibody exhibit antagonist activity of the anti-CD40 antibody; antiproliferative agents; controlling cell differentiation; anticarcinogenic agents; Hodgkin's disease, leukemias
10/26/2010US7820169 inhibiting the activity of tumor necrosis factor TNF in a patient having rheumatoid arthritis or psoriatic arthritis, by administering a composition comprising an effective amount of human anti-TNF antibody comprising a heavy chain variable region comprising SEQ ID NO:7 and a light chain variable
1 ... 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 ... 1823